Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-Drug Interaction Study of ZX008 in Healthy Participants
NCT06679413Phase 1Completed
- Sponsor
- UCB
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fenfluramine in epilepsy, sponsored by UCB. Primary endpoints: Maximum Concentration at Day 22, Area Under the Curve From 0 to Infinity at Day 22 and 1 more. Started Dec 2024; status: completed.
02
Drugs
fenfluramine
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06679413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679413.